Pyxis Oncology, Inc.

Pyxis Oncology is a clinical-stage biopharmaceutical company that develops targeted cancer therapies for individuals with difficult-to-treat solid tumors. The company focuses primarily on treating recurrent and metastatic head and neck squamous cell carcinoma. Its lead investigational product candidate is micvotabart pelidotin, an antibody-drug conjugate designed to target an extracellular matrix protein variant within tumor microenvironments. The company evaluates this drug candidate both as a single-agent monotherapy and in combination with other cancer immunotherapies across various solid tumor types, including breast, cervical, and gastric cancers. It also maintains technology platforms for antibody discovery and conjugate design. The target population consists of cancer patients with advanced solid malignancies who require further intervention after initial systemic therapies.

The company conducts clinical development activities internationally, maintaining clinical trial sites across the United States, the European Union, and several other countries. Its operations are driven by a multidisciplinary workforce covering research, clinical development, and corporate administration. The provided text does not state the location of the company's headquarters.

Summary of the business section of Pyxis Oncology's latest annual report, written by StockData.

“As of March 20, 2026, we had 56 full-time permanent employees.”